8-K: Cytokinetics' Aficamten Shows Sustained Benefits in Hypertrophic Cardiomyopathy Patients

Cytokinetics announced positive 48-week data from the FOREST-HCM study, demonstrating significant and sustained improvements in patients with hypertrophic cardiomyopathy treated with aficamten.

Summary

• Cytokinetics released additional 48-week data from the FOREST-HCM open-label extension study of aficamten in patients with hypertrophic cardiomyopathy (HCM).
• The study enrolled 213 patients with obstructive HCM between May 28, 2021, and October 31, 2023.
• The updated data focuses on 46 patients who completed 48 weeks of follow-up.
• At week 48, 75% of patients were receiving a 15 mg or 20 mg dose of aficamten.
• Treatment with aficamten resulted in substantial and sustained reductions in average resting LVOT-G (mean change of -39.6 mmHg) and Valsalva LVOT-G (mean change of -53.2 mmHg).
• There were statistically significant improvements in NYHA Functional Class, with 82.2% of patients improving by one class and no instances of worsening.
• The study also showed significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline.
• Aficamten treatment led to improvements in cardiac structure and function, including decreases in maximum wall thickness (mean change of -0.12 cm), left atrial volume index (mean change of -3.5 mL/m2), and lateral E/e (mean change of -2.2).
• The study showed a 94% reduction in SRT eligibility after six months of treatment with aficamten.
• Aficamten was well-tolerated, with no treatment-related serious adverse events.
• There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change of -5.1 mg).

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with significant improvements in key metrics and good tolerability, suggesting a strong potential for the drug. However, the forward-looking statements and the modest reduction in LVEF prevent a perfect score.

Positives

• Aficamten showed significant and sustained reductions in LVOT-G, a key measure of the severity of HCM.
• A large majority of patients experienced an improvement in their NYHA functional class, indicating better quality of life.
• The reduction in NT-proBNP suggests a decrease in cardiac wall stress.
• Improvements in cardiac structure and function were observed, including decreases in maximum wall thickness and left atrial volume index.
• The significant reduction in SRT eligibility suggests that aficamten could reduce the need for invasive procedures.
• The drug was well-tolerated with no treatment-related serious adverse events.

Negatives

• There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change of -5.1 mg).
• Three patients required dose down-titration due to LVEF <50%.

Risks

• The modest reduction in LVEF could be a concern for some patients and requires monitoring.
• The need for dose down-titration in some patients due to LVEF <50% indicates a potential risk that needs to be managed.
• The forward-looking statements are subject to various risks and uncertainties, including regulatory approval.

Future Outlook

The company is seeking regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy, but there are no guarantees of future performance.

Industry Context

This announcement is significant in the context of the treatment of hypertrophic cardiomyopathy, a condition with limited treatment options. The positive results from the FOREST-HCM study could position aficamten as a key therapy in this space.

Comparison to Industry Standards

• Current treatments for HCM include beta-blockers, calcium channel blockers, and disopyramide, which primarily manage symptoms but do not address the underlying cause of the disease.
• Septal reduction therapy (SRT), such as surgical myectomy or alcohol septal ablation, is an invasive procedure reserved for severe cases.
• The results of aficamten, particularly the reduction in SRT eligibility, suggest a potential for a less invasive treatment option.
• Compared to other investigational drugs for HCM, aficamten's results show a strong profile in terms of efficacy and tolerability.
• Companies like Bristol Myers Squibb and MyoKardia (now part of BMS) are also developing treatments for HCM, but aficamten's data appears competitive.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data.
• Patients with HCM may have a new and effective treatment option.
• Healthcare providers may see aficamten as a valuable addition to their treatment arsenal.

Next Steps

• The company will continue to pursue regulatory approval for aficamten.
• Further analysis of the data from the FOREST-HCM study may be conducted.

Key Dates

Keywords

aficamten, hypertrophic cardiomyopathy, HCM, LVOT-G, NYHA Functional Class, NT-proBNP, cardiac biomarkers, septal reduction therapy, SRT, LVEF